HOME > Business Wire > Article

April 15, 2021 17:12 UTC

Hemophilia B Epidemiology Forecast Report 2020-2030: Focus on United States, Germany, France, Italy, Spain, United Kingdom, and Japan - ResearchAndMarkets.com

DUBLIN--(BUSINESS WIRE)-- The "Hemophilia B - Epidemiology Forecast to 2030" report has been added to ResearchAndMarkets.com's offering.

This 'Hemophilia B - Epidemiology Forecast to 2030' report delivers an in-depth understanding of the disease, historical and forecasted Hemophilia B epidemiology in the 7MM, i.e., the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

Epidemiology Perspective

The Hemophilia B epidemiology division provides the insights about historical and current Hemophilia B patient pool and forecasted trend for each seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

In 2020, the overall prevalent cases of Hemophilia B accessed to be around 10,739 in the 7MM, which are expected to grow during the study period, i.e., 2018-2030.

The disease epidemiology covered in the report provides historical as well as forecasted Hemophilia B epidemiology [segmented as Total diagnosed Prevalent Pool of Hemophilia B, Severity-specific Prevalent Pool of Hemophilia B, Prevalent population of Hemophilia B with or without Inhibitors and Treated Prevalent Population of Hemophilia B] in the 7MM, covering the United States, EU5 countries (Germany, France, Italy, Spain, and United Kingdom), and Japan from 2020 to 2030.

Key Topics Covered:

1. Key Insights

2. Executive Summary of Hemophilia B

3. Epidemiology an d Market Methodology

4. Hemophilia B: Disease Background and Overview

4.1. Classification of Hemophilia

4.2. Sign and Symptoms of Hemophilia B

4.3. The severity of Hemophilia B

4.4. Risk factors and causes of Hemophilia B

4.5. Pathophysiology

4.6. Genetics of Hemophilia B

4.7. Hemophilia and Inhibitors

4.8. Diagnosis

4.9. Diagnostic Algorithm

4.10. Differential diagnosis of Hemophilia B

4.11. Diagnostic Guidelines for Emergency Department Management of Individuals with Hemophilia and Other Bleeding Disorders

4.12. World Federation of Hemophilia (WFH) Guidelines for Diagnosis of Hemophilia

5. Epidemiology and Patient Population

5.1. Epidemiology Key Findings

5.2. Assumptions and Rationale: 7MM

5.3. Epidemiology Scenario: 7MM

5.3.1. Total Diagnosed Prevalent Population of Hemophilia B in the 7MM

5.3.2. Severity- Specific Prevalent Population of Hemophilia B in the 7MM

5.3.3. Prevalent population of Hemophilia B with or without Inhibitors the 7MM

5.3.4. Treated Prevalent Population of Hemophilia B in the 7MM

5.4. United States Epidemiology

5.5. EU-5 Country-wise Epidemiology

5.6. Germany Epidemiology

5.7. France Epidemiology

5.8. Italy Epidemiology

5.9. Spain Epidemiology

5.10. United Kingdom Epidemiology

5.11. Japan Epidemiology

6. Appendix

For more information about this report visit https://www.researchandmarkets.com/r/j8lm8t


Laura Wood, Senior Press Manager

For E.S.T Office Hours Call 1-917-300-0470
For U.S./CAN Toll Free Call 1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

Source: Research and Markets

View this news release online at:

The content of this press release is provided by Business Wire. If you
have any questions regarding the content, please contact the person(s)
identified in the CONTACTS box at the bottom of the release.

Business Wire

Aomori Tourism Information


Okinawa Gov. Tamaki Aporolizes for Having Home BBQ Parties amid Quasi-Emergency
JAL Posts Net Loss of 286.6 B. Yen for FY 2020, 1st Red Ink since Relisting
Sumo: Yokozuna Hakuho to Miss 6th Straight Grand Tourney
Tokyo Sees 907 New Coronavirus Cases